Copyright
©The Author(s) 2020.
World J Clin Cases. Jul 26, 2020; 8(14): 2917-2929
Published online Jul 26, 2020. doi: 10.12998/wjcc.v8.i14.2917
Published online Jul 26, 2020. doi: 10.12998/wjcc.v8.i14.2917
Figure 3 The higher APEX2 level shows a lower overall survival rate.
A: The total liver hepatocellular carcinoma patients, B: Patients with AJCC-T1 stage, C: Patients with positive hepatitis virus, D: Patients with negative hepatitis virus were divided into two groups (high or low-level group). The best cut-off was achieved by the interactive tool of Kaplan Meier plotter, and the overall survival rate was analyzed in 5-year following up. HR: Hazard ratio; OS: Overall survival; AJCC: The American Joint Committee on Cancer.
- Citation: Zheng R, Zhu HL, Hu BR, Ruan XJ, Cai HJ. Identification of APEX2 as an oncogene in liver cancer. World J Clin Cases 2020; 8(14): 2917-2929
- URL: https://www.wjgnet.com/2307-8960/full/v8/i14/2917.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i14.2917